After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up ...

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received ...

The first-of-its-kind Edwards Lifesciences Sapien M3 TMVR system uses a nitinol dock to anchor the replacement valve in the patient's heart.

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...

Edwards SAPIEN M3 mitral valve replacement system receives CE Mark for transcatheter treatment: Irvine, California Wednesday, ...

Edwards Lifesciences announced today that it received CE mark approval for its Sapien M3 mitral valve replacement system.

Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...

Mitral regurgitation is the most common form of valvular heart disease and affects around 10% of Americans over 75. It occurs when the mitral ...

Bhubaneswar: The Kalinga Institute of Medical Sciences (KIMS) is leading the way in Odisha by offering complex heart ...

The Irvine-based medical device maker today announced that it received CE mark approval for its Sapien M3 mitral replacement ...